Ritlecitinib

(Litfulo®)

Ritlecitinib

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormCapsule (oral; 50 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for or the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ritlecitinib (Litfulo) is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older, demonstrating notable efficacy among Janus kinase (JAK) inhibitors. This drug shows competitive performance compared to other JAK inhibitors such as baricitinib.
  • Five systematic reviews/meta-analyses provided a comprehensive analysis focusing on ritlecitinib's safety, efficacy, and specific considerations for various populations and subgroups where available.
  • In terms of effectiveness against alopecia areata, oral JAK inhibitors, including ritlecitinib, have shown significant hair regrowth potential when compared to other treatments like PDE-4 inhibitors or biologics which have limited efficacy so far.
  • Safety profile assessments reveal that while side effects such as acne and headaches may occur with ritlecitinib use, it has a manageable safety profile with risks comparable to placebo for upper respiratory tract infections. Most adverse events were mild, indicating good tolerability of this drug.
  • Randomized controlled trials did not show any significant difference between oral JAK inhibitor users versus control groups in experiencing most types of adverse events, suggesting a favorable safety profile overall. Adverse event reports from non-RCTs were mostly mild, aligning well with the general characterization seen.
  • Although there is an absence of detailed subgroup analysis or population-specific considerations within these studies, some evidence suggests better outcomes in certain non-RCT subgroups using different JAK inhibitors, hinting at possible variations based on patient characteristics, but more comprehensive data would be needed for definitive conclusions.